Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Benefit in Phase 3 Trial

By Public Technologies
  • BioNTech and DualityBio reported trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial.
  • Progression-free survival improved significantly but modestly versus chemotherapy in chemotherapy-naive patients with HR-positive, HER2-low metastatic breast cancer progressing on endocrine therapy.
  • Interim overall survival data were not yet mature.
  • Interstitial lung disease occurred more frequently than in earlier studies; most cases were mild or moderate, but some were severe or fatal.
  • The partners see limited potential benefit relative to available treatments and will review the data to decide next steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.